APRE NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Aprea Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 0.63 USD
-10.9% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -21.9% below the Trend Line and sits at 6.1% of its 52-week range. The latest completed week returned -10.9%, after a -20.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 9 out of 100
Latest Close 0.63 USD 24 Jul 2026
1W Return -10.9% latest completed week
4W Return -20.0% short-term follow-through
12W Return -22.7% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.2x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -10.9% Latest completed week; four-week move -20.0%. Indicator stack 0/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 38.99% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 53/100 51 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -21.9% below the Trend Line and sits at 6.1% of its 52-week range. The latest completed week returned -10.9%, after a -20.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.2x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1812-week average 0.23

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.18Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -20.0% over four weeks, -22.7% over 12 weeks, and -66.6% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-10.9%
4W-20.0%
12W-22.7%
26W-23.9%
52W-66.6%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.37Latest activity-pressure read.
Pressure change-588.6%Four-week change in activity pressure.
Leadership-45.71Latest relative-leadership reading.
RS change-14.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength73/100Blend of value, momentum, and quality. Underlying universe rank 28; rank 1 is best.
Value61/100Relative valuation strength. Underlying universe rank 40; rank 1 is best.
Quality59/100Profitability and accounting quality. Underlying universe rank 42; rank 1 is best.
Momentum61/100Medium-term price momentum. Underlying universe rank 40; rank 1 is best.
Growth61/100Revenue and earnings growth. Underlying universe rank 40; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
63.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-156.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
2091.9%
Gross profit retained from each unit of revenue.
Operating margin
-9696.0%
Operating profit retained from revenue.
Free-cash-flow margin
-9909.1%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-90.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.9x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity16 / 0

16 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment53/100

Weighted news tone is neutral across 51 relevant articles.

9 positive · 36 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-67.3%Distance below the 52-week high.
13-week volatility9.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+28.2%Week of 10 Apr.
Worst week-18.2%Week of 13 Mar.
Latest week-10.9%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains3
Flat weeks0
Modest losses1
Sharp losses14
Recent vol9.5%13-week weekly-return volatility.
Base vol10.2%52-week weekly-return volatility.
Up/down split18/33Count of positive and negative weeks in the 52-week window.
Average skew9.4% / -7.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape10/100

Trend, activity pressure, participation, and risk combine to a 10/100 tape read.

 Indicator analysis29/100

Latest 12-week confirmation: trend 0/12, activity pressure 10/12, relative leadership 0/12.

Activity pressure 0.18; No reversal markers Next-Week ExpectancyNegative 38.99%

Next-week expectancy is negative with a 38.99% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors63/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 51 relevant articles.

Aprea Therapeutics Inc (APRE) Financial Health: Profitability & Balance Sheet Analysis Insiders16 / 0

16 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.63 USD-10.9%0.81 USD2.88 USD-0.37-45.71140.0KOff
17 Jul 20260.71 USD-4.8%0.82 USD2.89 USD-0.12-41.63349.4KOff
10 Jul 20260.74 USD0.5%0.83 USD2.91 USD0.02-42.49237.9KOff
3 Jul 20260.74 USD-6.2%0.83 USD2.92 USD0.03-43.06467.3KOff
26 Jun 20260.79 USD10.5%0.84 USD2.94 USD0.08-40.09607.4KOff
19 Jun 20260.71 USD4.2%0.86 USD2.95 USD0.32-49.24289.0KOff
12 Jun 20260.69 USD-7.5%0.88 USD2.97 USD0.65-51.05700.1KOff
5 Jun 20260.74 USD-16.9%0.89 USD2.99 USD0.96-47.22644.0KOff
29 May 20260.89 USD-6.0%0.91 USD3.00 USD1.23-40.61437.6KOff
22 May 20260.95 USD2.1%0.93 USD3.02 USD1.15-36.26952.9KOff
15 May 20260.93 USD-5.1%0.94 USD3.04 USD1.10-37.97773.3KOff
8 May 20260.98 USD19.8%0.96 USD3.06 USD1.10-36.181.7MOff
1 May 20260.82 USD-12.0%0.98 USD3.07 USD1.07-44.75623.6KOff
24 Apr 20260.93 USD-7.0%1.00 USD3.09 USD0.98-37.641.1MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.